Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 23.03.2026 1 AAPS J 1 ACS Appl Bio Mater 2 Actas Urol Esp (Engl Ed) 1 Adv Sci (Weinh) 1 Am Soc Clin Oncol Educ Book 1 Ann Nucl Med 1 Ann Surg Oncol 1 Biochem Pharmacol 4 BJU Int 1 BMC Cancer 1 Cancer Epidemiol 1 Cancer Manag Res 1 Cancer Med 1 Cancer Rep (Hoboken) 1 Cancer Treat Res Commun 2 Cancers (Basel) 1 Cell Biol Toxicol 1 Cell Oncol (Dordr) 1 Cell Signal 3 Clin Genitourin Cancer 2 Crit Rev Oncol Hematol 2 Cureus 1 Environ Pollut 1 Eur Urol Oncol 2 Exp Mol Pathol 1 Front Cell Dev Biol 3 Front Oncol 1 Int J Med Inform 2 Int J Mol Sci 1 Int J Urol 2 Int Urol Nephrol 1 J Bioenerg Biomembr 1 J Clin Med 1 J Control Release 1 J Geriatr Oncol 1 J Surg Case Rep 1 J Urol 1 J Vet Med Sci 1 Lancet Prim Care 1 Magn Reson Med Sci 1 Medicine (Baltimore) 1 Neurourol Urodyn 1 Pathol Oncol Res 1 Pediatr Transplant 1 Prague Med Rep 2 Q J Nucl Med Mol Imaging 1 Rev Esp Enferm Dig 1 Sci Rep 1 Semin Diagn Pathol 1 Small 1 Strahlenther Onkol 1 Tissue Cell 3 Urol Oncol 1 Urol Pract 1 Urology 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AAPS J

1. LONG M, Peng Y, Gade S, Nicholson H, et al
   Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach.
   AAPS J. 2026;28:74.
   PubMed         Abstract available
   
   

   
   ACS Appl Bio Mater

2. RIBEIRO CPS, Fernandes R, Lourenco LMO
   Smart Macrocycles: Cyclodextrin-Porphyrin Photosensitizers for Photodynamic Therapy in Human Bladder Cancer Cells.
   ACS Appl Bio Mater. 2026 Mar 18:XXX. doi: 10.1021/acsabm.6c00053.
   PubMed         Abstract available
   
   

   
   Actas Urol Esp (Engl Ed)

3. CANO-VELASCO J, Luis-Cardo A, Moreno-Cortes JC, Carrasco-Loras L, et al
   Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.
   Actas Urol Esp (Engl Ed). 2026 Mar 16:501937. doi: 10.1016/j.acuroe.2026.501937.
   PubMed         Abstract available
   
   
4. FELTES BENITEZ N, Counago F, Paredes-Rubio S, Peleteiro Higuero P, et al
   Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study.
   Actas Urol Esp (Engl Ed). 2026 Mar 16:501967. doi: 10.1016/j.acuroe.2026.501967.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

5. XU X, Liang R, Zhao A, Zhang J, et al
   Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer.
   Adv Sci (Weinh). 2026 Mar 20:e74876. doi: 10.1002/advs.74876.
   PubMed         Abstract available
   
   

   
   Am Soc Clin Oncol Educ Book

6. LI J, Ballas L, Ghatalia P
   Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.
   Am Soc Clin Oncol Educ Book. 2026;46:e515984.
   PubMed         Abstract available
   
   

   
   Ann Nucl Med

7. SABER TANHA A, Sadeghi R, Ghorbani H, Soltani S, et al
   Lymphatic mapping and sentinel lymph node biopsy in urinary bladder cancer: A SPECT/CT-based experience.
   Ann Nucl Med. 2026 Mar 13. doi: 10.1007/s12149-026-02181.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

8. SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
   Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer.
   Ann Surg Oncol. 2026 Mar 20. doi: 10.1245/s10434-026-19476.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

9. CHENG H, Lu L, Gong Y, Liu S, et al
   Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy.
   Biochem Pharmacol. 2026 Mar 16:117905. doi: 10.1016/j.bcp.2026.117905.
   PubMed         Abstract available
   
   

   
   BJU Int

10. ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
    Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
    BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
    PubMed         Abstract available
    
    
11. SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
    Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
    BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
    PubMed        
    
    
12. 
    Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
    PubMed        
    
    
13. SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
    Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
    Mumio and bladder cancer: unlocking its potential in 3D cell culture.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
    PubMed        
    
    

    
    Cancer Epidemiol

15. VANEGAS CARDENAS SA, Cantor EJ, de Vries E
    Incidence, mortality, and five-year survival of bladder cancer in six population-based cancer registries in Colombia, 2003-2018.
    Cancer Epidemiol. 2026;102:103049.
    PubMed         Abstract available
    
    

    
    Cancer Manag Res

16. MAHDIPOUR S, Modarressi MH, Noruzinia M
    Methylation and Expression Analysis of POU4F2, HOXA9, RBM46, and TSGA10 Genes in Bladder Cancer Using Methyl-Sensitive Restriction Enzyme PCR (MSRE-PCR).
    Cancer Manag Res. 2026;18:557943.
    PubMed         Abstract available
    
    

    
    Cancer Med

17. HU X, Miao J, Huang Y, Yang Y, et al
    Urinary Diversion-Specific Morbidity After Radical Cystectomy: A Ten-Year Institutional Experience.
    Cancer Med. 2026;15:e71684.
    PubMed         Abstract available
    
    

    
    Cancer Rep (Hoboken)

18. DOUMANIDIS P, Tsagkozis P
    Surgical Management of Bone Metastases in Bladder Cancer: A Single-Center Retrospective Study.
    Cancer Rep (Hoboken). 2026;9:e70524.
    PubMed         Abstract available
    
    

    
    Cancer Treat Res Commun

19. PORRECA A, Marino F, De Marchi D, Giampaoli M, et al
    Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?
    Cancer Treat Res Commun. 2026;47:101181.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

20. VENKATESH A, Rodriguez Rosales RD, Kanumuambidi JP, Ishiyama Y, et al
    Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.
    Cancers (Basel). 2026;18:875.
    PubMed         Abstract available
    
    
21. KIM T, Shin D, Ahn HK, Moon YJ, et al
    Urine-Based cfDNA Ensemble Modeling for Early Detection of Bladder Cancer Using Whole-Genome Methylation Sequencing.
    Cancers (Basel). 2026;18:767.
    PubMed         Abstract available
    
    

    
    Cell Biol Toxicol

22. LIU Y, Tang A, Wang H
    Toxicogenomic Characterization of Perfluorooctanoic Acid-Associated Bladder Carcinogenesis.
    Cell Biol Toxicol. 2026;42:47.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

23. HU Z, Jiang N, Xie B, Zhou J, et al
    CircBARD1 suppresses tumor progression driven by H3K18 lactylation-CCNA2 axis in human bladder cancer.
    Cell Oncol (Dordr). 2026;49:58.
    PubMed        
    
    

    
    Cell Signal

24. ZHANG L, Chen C, Huang W, Dong L, et al
    PIN1 suppresses bladder cancer progression by inducing cellular senescence and activating the interferon response pathway.
    Cell Signal. 2026;143:112476.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

25. ZHU J, Ma X, Xie F, Wang Y, et al
    TNM Stage-Stratified Comparison Between Urachal and Nonurachal Adenocarcinomas of the Bladder: A Single-Center Retrospective Cohort Study.
    Clin Genitourin Cancer. 2026;24:102509.
    PubMed         Abstract available
    
    
26. ASLANOVA M, Pereanu W, Lawrence A, Wang H, et al
    Tumor-Informed Circulating Tumor DNA (ctDNA) in Locally Advanced and Metastatic Urothelial Carcinoma: A Retrospective Single-Center Cohort.
    Clin Genitourin Cancer. 2026;24:102512.
    PubMed         Abstract available
    
    
27. PARIKH M, McMahon P, Eng S, Boateng F, et al
    Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan.
    Clin Genitourin Cancer. 2026;24:102516.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

28. ZHAO K, Zhou Z, Ma X, Xiao X, et al
    Progress and challenges in CAR-T cell therapy for bladder cancer.
    Crit Rev Oncol Hematol. 2026;222:105275.
    PubMed         Abstract available
    
    
29. TANG Y, Wang L, Liu H, Zhu Q, et al
    Advances in intravesical therapy for non-muscle-invasive bladder cancer.
    Crit Rev Oncol Hematol. 2026;222:105271.
    PubMed         Abstract available
    
    

    
    Cureus

30. BOUNOUAR O, El Moudane A, Andrea E, Jdaini A, et al
    Urothelial Bladder Cancer With Cardiac Metastasis: A Case Report.
    Cureus. 2026;18:e103414.
    PubMed         Abstract available
    
    
31. LEASK J, Ibrahim I, Wilson B, Hendry J, et al
    The Role of Socioeconomic Status in Influencing Stage at Presentation and Overall Survival in Bladder Cancer: Experience From the West of Scotland.
    Cureus. 2026;18:e103399.
    PubMed         Abstract available
    
    

    
    Environ Pollut

32. JIE J, Wang Q, Chen Z, Hu C, et al
    Multi-omics analysis and preliminary experimental validation of acetyl tributyl citrate (ATBC) promoting bladder cancer progression via the AKR1B1/EMT axis.
    Environ Pollut. 2026;397:127970.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

33. DUQUESNE I, Epelbaum I, Prost D, Haberstich M, et al
    Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.
    Eur Urol Oncol. 2026 Mar 19:S2588-9311(26)00065.
    PubMed         Abstract available
    
    

    
    Exp Mol Pathol

34. SAKATANI T, Tanaka S, Murakami K, Jinno C, et al
    Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
    Exp Mol Pathol. 2026;146:105039.
    PubMed         Abstract available
    
    
35. LOMBARDO KA, Yoshida T, Johnson E, Fitzgerald K, et al
    Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.
    Exp Mol Pathol. 2026;145:105032.
    PubMed         Abstract available
    
    

    
    Front Cell Dev Biol

36. YU H, Lei Q, Yang W, Cao M, et al
    FAM-related prognostic molecular subtype screening identified epithelial-derived MAOA-inhibiting bladder cancer.
    Front Cell Dev Biol. 2026;14:1732999.
    PubMed         Abstract available
    
    

    
    Front Oncol

37. SUN L, Liu C, Yuan L
    Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).
    Front Oncol. 2026;16:1713506.
    PubMed         Abstract available
    
    
38. HE J, Liu X, Li S, Xia Z, et al
    A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.
    Front Oncol. 2026;16:1754912.
    PubMed         Abstract available
    
    
39. WU Q, Zhou Y, Ou Z, Fu H, et al
    Peroxisomal activity drives aggressive bladder cancer phenotypes and reveals erythorbic acid as a potential therapeutic modulator.
    Front Oncol. 2026;16:1734437.
    PubMed         Abstract available
    
    

    
    Int J Med Inform

40. HJORT PB, Jensen JE, Jensen JB, Ernst A, et al
    Study of bladder cancer detection in standard white light versus AI-supported endoscopy-01 (RAISE-01) - Development and validation of an AI-based support tool.
    Int J Med Inform. 2026;213:106390.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

41. DOMIAN N, Smereczanska M, Mrugacz M, Mlynarczyk G, et al
    Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:2089.
    PubMed         Abstract available
    
    
42. PARRAO D, Gallegos H, Ruz K, Lay R, et al
    Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer.
    Int J Mol Sci. 2026;27:2237.
    PubMed         Abstract available
    
    

    
    Int J Urol

43. GOTO Y
    Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
    Int J Urol. 2026;33:e70405.
    PubMed        
    
    

    
    Int Urol Nephrol

44. TANG C, Wang T, Luo H, Xue J, et al
    Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.
    Int Urol Nephrol. 2026;58:1291-1306.
    PubMed         Abstract available
    
    
45. SRIVASTAVA A, Trivedi S, Singh Y, Kumar U, et al
    Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.
    Int Urol Nephrol. 2026 Mar 17. doi: 10.1007/s11255-026-05067.
    PubMed         Abstract available
    
    

    
    J Bioenerg Biomembr

46. WANG Y, Zhang A, Che H, Gao J, et al
    Coenzyme Q10 exerts anti-cancer effects in bladder cancer by inducing ROS-mediated apoptosis and autophagy.
    J Bioenerg Biomembr. 2026 Mar 19. doi: 10.1007/s10863-026-10093.
    PubMed        
    
    

    
    J Clin Med

47. MELGAREJO SEGURA MT, Herraez Marcos M, Cano Garcia MC, Zambudio Munuera A, et al
    De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration.
    J Clin Med. 2026;15:1939.
    PubMed         Abstract available
    
    

    
    J Control Release

48. HUANG L, Sun X, Song T, Liu Z, et al
    Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer.
    J Control Release. 2026;393:114808.
    PubMed         Abstract available
    
    

    
    J Geriatr Oncol

49. BAHAR P, Perez-Londono A, Kaul S, Efstathiou J, et al
    Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults.
    J Geriatr Oncol. 2026;17:102939.
    PubMed         Abstract available
    
    

    
    J Surg Case Rep

50. ALWABEL W, Almisfer A, Alsamaani I, Aljaafri B, et al
    Intravesical therapy for bladder cancer causing disseminated tuberculosis and perforated viscus: a case report.
    J Surg Case Rep. 2026;2026:rjag131.
    PubMed         Abstract available
    
    

    
    J Urol

51. BEN-DAVID R, Raizenne BL, Eraky A, Duquesne I, et al
    Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2026 Mar 17:101097JU0000000000005034. doi: 10.1097/JU.0000000000005034.
    PubMed         Abstract available
    
    

    
    J Vet Med Sci

52. KOMORI M, Ogawa M, Yonezawa T, Momoi Y, et al
    Significance of monocyte-to-lymphocyte ratio as a prognostic factor in canine urothelial carcinoma: a retrospective study.
    J Vet Med Sci. 2026;88:485-491.
    PubMed         Abstract available
    
    

    
    Lancet Prim Care

53. MAHATI SG, Wu J, Walter FM, Zhou Y, et al
    Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case-control study.
    Lancet Prim Care. 2026;2:None.
    PubMed         Abstract available
    
    

    
    Magn Reson Med Sci

54. WATANABE H, Takeuchi M, Higaki A, Kojima Y, et al
    Histopathological Basis of Peritumoral Enhancement in Muscle-invasive Bladder Cancer.
    Magn Reson Med Sci. 2026 Mar 19. doi: 10.2463/mrms.mp.2025-0211.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

55. BAI J
    Impact of physiological ability and surgical stress score on postoperative complications in patients undergoing surgery for non-muscle-invasive bladder cancer.
    Medicine (Baltimore). 2026;105:e47699.
    PubMed         Abstract available
    
    

    
    Neurourol Urodyn

56. GERSHMAN B, Perez-Londono A, Almohtasib J, Kaul S, et al
    Voiding Dysfunction Among Older Adults With Non-Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder.
    Neurourol Urodyn. 2026 Mar 19. doi: 10.1002/nau.70269.
    PubMed         Abstract available
    
    

    
    Pathol Oncol Res

57. VARADI M, Magyar B, Szeles A, Korda S, et al
    Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer.
    Pathol Oncol Res. 2026;32:1612333.
    PubMed         Abstract available
    
    

    
    Pediatr Transplant

58. ICHAS M, Allard L, Harper L, Yacoub M, et al
    Urothelial Carcinoma of the Bladder Following BK Virus Infection in a Pediatric Kidney Transplant Recipient.
    Pediatr Transplant. 2026;30:e70303.
    PubMed         Abstract available
    
    

    
    Prague Med Rep

59. TURAN S, Gezmis CT, Israfilov A, Aydin M, et al
    Primary Mucinous Bladder Adenocarcinoma.
    Prague Med Rep. 2026;127:44-47.
    PubMed         Abstract available
    
    

    
    Q J Nucl Med Mol Imaging

60. GUGLIELMO P, Perrone E, Librando M, Aghaee A, et al
    Novel radiopharmaceuticals for bladder cancer evaluation.
    Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03706.
    PubMed         Abstract available
    
    
61. EVANGELISTA L, Guglielmo P
    From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.
    Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03731.
    PubMed        
    
    

    
    Rev Esp Enferm Dig

62. BAS-CUTRINA F, Morales-Alvarado VJ, Gomis-Marti M, Jimenez-Serrano E, et al
    Endoscopic vacuum therapy for leaky cavities: is it possible?
    Rev Esp Enferm Dig. 2026;118:112-114.
    PubMed         Abstract available
    
    

    
    Sci Rep

63. ZHANG C, Cao S, Zeng G, Dong Y, et al
    APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.
    Sci Rep. 2026 Mar 15. doi: 10.1038/s41598-026-44653.
    PubMed        
    
    

    
    Semin Diagn Pathol

64. WU DJ, Chan E
    Histologic mimics of urothelial carcinoma.
    Semin Diagn Pathol. 2026;43:150993.
    PubMed         Abstract available
    
    

    
    Small

65. YAO W, Shen W, Zhou H, Dai X, et al
    Bioinspired IgM-Mimetic Polyvalent Aptamer-Albumin Nanoplatform for Targeted Intravesical Therapy of Bladder Cancer.
    Small. 2026 Mar 19:e14393. doi: 10.1002/smll.202514393.
    PubMed         Abstract available
    
    

    
    Strahlenther Onkol

66. DUNST J
    [Cystectomy plus perioperative enfortumab vedotin/pembrolizumab in bladder cancer].
    Strahlenther Onkol. 2026;202:448-450.
    PubMed        
    
    

    
    Tissue Cell

67. KOLAHI AZAR H, Beheshtizadeh N, Rezapour R, Pourlak T, et al
    p16 positivity as a potent indicator of high-grade histology and its interplay with HER2/neu in urothelial bladder carcinoma.
    Tissue Cell. 2026;100:103390.
    PubMed         Abstract available
    
    

    
    Urol Oncol

68. PEARSON M, Engen PA, Green SJ, Emerson J, et al
    Microbial profiling of urothelial carcinoma and benign bladder tissue from formalin-fixed specimens.
    Urol Oncol. 2026;44:110997.
    PubMed         Abstract available
    
    
69. BRACARDA S, Mammone G, Mosillo C, Sirgiovanni G, et al
    Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting.
    Urol Oncol. 2026;44:110986.
    PubMed         Abstract available
    
    
70. MARDELLI C, Bertail T, Tachibana I, Verhoest G, et al
    Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence.
    Urol Oncol. 2026 Mar 13:111047. doi: 10.1016/j.urolonc.2026.111047.
    PubMed         Abstract available
    
    

    
    Urol Pract

71. ASSEL M, Vickers AJ
    Letter: Incarcerated Patients Present With More Advanced Bladder Cancer Stage: A Statewide Analysis.
    Urol Pract. 2026 Mar 16:101097UPJ0000000000000987.
    PubMed        
    
    

    
    Urology

72. SMELSER WW
    Editorial Commentary: "Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
    Urology. 2026 Mar 17:S0090-4295(26)00177-9. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

    
    World J Urol

73. KITANO H, Watanabe E, Tadera K, Nakano Y, et al
    Urine culture-guided antibiotic prophylaxis reduces febrile pyelonephritis after ureteral stent removal following radical cystectomy.
    World J Urol. 2026;44:249.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum